Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan

International Journal of Clinical Oncology
Hisashi Uhara

Abstract

New therapeutic strategies including immunotherapy and selective molecular target inhibitors have brought about a new era in the treatment of patients with advanced melanoma. In Japan, the immune checkpoint inhibitors ipilimumab, nivolumab and pembrolizumab, the BRAF inhibitor (BRAFi) vemurafenib, dabrafenib and MEK inhibitor (MEKi) trametinib have been available for the treatment of unresectable and metastatic melanoma. The BRAFi + MEKi combination shows high response rates (60-70%) and rapid response induction associated with symptom control, with a progression-free survival of 12 months. Nivolumab and pembrolizumab offer moderate response rates (30-40%) and long survival (3- to 5-year survival: 30-50%). In Japan, treatment options for the first-line setting frequently include nivolumab or pembrolizumab monotherapy and BRAFi + MEKi combinations (for patients with BRAF-mutant melanoma). Ipilimumab is included in the second-line setting, and the nivolumab + ipilimumab combination has not been approved yet in Japan. Although these medications have demonstrated impressive efficacy, the clinical trials and real-world data have shown that the clinical benefit is not fully satisfactory. We have to carefully manage a new class of adv...Continue Reading

References

Nov 18, 2005·The New England Journal of Medicine·John A CurtinBoris C Bastian
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John A CurtinBoris C Bastian
Jan 30, 2008·Journal of Dermatological Science·Daisuke WatanabeYukihiro Nishiyama
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Jan 28, 2012·British Journal of Cancer·K SakaizawaR Okuyama
Apr 27, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander M MenziesGeorgina V Long
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Oct 2, 2012·The New England Journal of Medicine·Keith T FlahertyJeffrey Weber
Jun 7, 2013·International Journal of Clinical Oncology·Hisashi UharaRyuhei Okuyama
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Sep 26, 2014·Cancer Nursing·Mika MiyashitaMiyako Takahashi
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 20, 2015·Cell·UNKNOWN Cancer Genome Atlas Network
Aug 19, 2015·Journal of Dermatological Science·Kaori SakaizawaHisashi Uhara
Sep 12, 2015·Science·Eliezer M Van AllenLevi A Garraway
Oct 9, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Morganna Freeman-KellerJeffrey Weber
Nov 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S KanameishiK Kabashima
Dec 30, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K A AhmedG T Gibney
Apr 29, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G MansonR Houot
May 4, 2017·Nature·Nicholas K HaywardGraham J Mann
Jul 5, 2017·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·H UharaN Yamazaki
Aug 20, 2017·Neurology·Shigeaki SuzukiMakoto Matsui
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Sep 12, 2017·The New England Journal of Medicine·Georgina V LongJohn M Kirkwood
Sep 12, 2017·The New England Journal of Medicine·Jeffrey WeberUNKNOWN CheckMate 238 Collaborators
Sep 26, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L KhojaA R Hansen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Lavinia SpainJames Larkin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Matteo S Carlino, Georgina V Long
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Igor N Ivashko, Jill M Kolesar
© 2022 Meta ULC. All rights reserved